(Q53012729)

10 May 2018

title

First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT. (English)

1 reference

10 May 2018

differentiated thyroid carcinoma

main subject

1 reference

Frederik A Verburg

1

1 reference

10 May 2018

Thomas Krohn

2

1 reference

10 May 2018

Alexander Heinzel

3

1 reference

10 May 2018

Felix M Mottaghy

4

1 reference

10 May 2018

Florian F Behrendt

5

1 reference

10 May 2018

publication date

28 April 2015

1 reference

10 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

number of pages

2

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

10 May 2018

volume

42

1 reference

10 May 2018

issue

10

1 reference

10 May 2018

page(s)

1622-1623

1 reference

10 May 2018

https://scigraph.springernature.com/pub.10.1007/s00259-015-3065-y

exact match

0 references

cites work

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3065-Y

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3065-Y

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3065-Y

Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3065-Y

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25916744

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-015-3065-Y

1 reference

10 May 2018

1 reference

10 May 2018